Psyched: First Australian Psych Company On Nasdaq, Utah’s Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results
On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of…
Novamind Posts Record High Revenue Of CA$2.45M, Up 32% QoQ
Psychedelics-focused mental health company Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE: HN2) reported its financial results for the three and six months ended December 31, 2021.
Benzinga’s Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022, in Miami, Florida.
Cancer Patients’ Case To Use Psilocybin Under Right To Try Law Dismissed By Fed Appeals Court
As the psychedelics space gains traction on many levels, a number of studies are being conducted to examine whether psychedelic medications can or should be used to treat depression in cancer patients.
Novamind Stock Dives On $3.95M Private Placement With Institutional Investor
Novamind Inc. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) announced Monday a CA$5 million ($3.95 million) private placement with an institutional investor.
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.
Novamind Opens Addiction Clinic In Utah, Establishing Substance Use Disorder Program
Novamind Inc. (OTCQB: NVMDF), a mental health company specializing in psychedelic medicine, has announced the launch of a new clinic located in downtown Salt Lake City specializing in integrative behavioral health and services for adults with substance use disorders.